Back to search

Article

The role of dopaminergic medication, lipid, and endocannabinoid pathway alterations in idiopathic and<i>PRKN/PINK1</i>-mediated Parkinson’s disease – a large-scale targeted metabolomics study

2024-03-02

Abstract excerpt

Alterations in many metabolites and biochemical pathways have been described in Parkinson’s Disease (PD). However, only a small fraction of these have been replicated in independent studies. As almost every PD patient is treated with dopaminergic medication, it is challenging to discriminate between disease- and drug-related effects, especially in relation to dopamine metabolism. We conducted a large-scale metabol...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
47295e37-2b70-5b2e-9a86-7746cdd60990
DOI
10.1101/2024.03.01.24303613
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The role of dopaminergic medication, lipid, and endocannabinoid pathway alterations in idiopathic and<i>PRKN/PINK1</i>-mediated Parkinson’s disease – a large-scale targeted metabolomics studyDOI 10.1101/2024.03.01.24303613
Levodopa and dopamine dynamics in Parkinson’s disease metabolomicsSemantic proximity
Biomarker Research in Parkinson’s Disease Using Metabolite ProfilingSemantic proximity
Untargeted <sup>1</sup> H NMR-based metabolomics reveal sex-based differences in blood metabolome profiles among patients with Parkinson’s disease, regardless of their idiopathic or genetic subtypeSemantic proximity
Multi-Omic Analysis Reveals Lipid Dysregulation Associated with Mitochondrial Dysfunction in Parkinson’s Disease BrainSemantic proximity
Discovery of Sexual Dimorphism in the Serum Metabolome of Parkinson’s Disease Patients Harboring Rare Genetic Variants with Uncertain PathogenicitySemantic proximity
Untargeted Plasma Metabolomics Unveils Distinct Metabolite Profiles in Parkinson’s Disease Subtypes: A Focus on idiopathic REM Sleep Behavior DisordersSemantic proximity
A metabolomic signature of treated and drug-naïve patients with Parkinson’s disease: a pilot studySemantic proximity
Parkinson’s Disease: Biomarkers, Treatment, and Risk FactorsSemantic proximity
Metabolomic Changes in Idiopathic and <i>GBA1</i> Parkinson’s DiseaseSemantic proximity
Sex differences impact serum metabolome profiles in patients with familial Parkinson’s diseaseSemantic proximity
Clinical Sphingolipids Pathway in Parkinson’s Disease: From GCase to Integrated-Biomarker DiscoverySemantic proximity
Brain-wide transcriptome-based metabolic alterations in Parkinson’s disease: human inter-region and human-experimental model correlationsSemantic proximity
Select a neighboring publication to make it the new centre.